Introduction
In all eukaryotic cells, microtubule, as one of the main components of the cell cytoskeleton, plays many different essential roles including the maintenance of cell shape, intracellular transport, cell motility, meiosis, and mitosis (Amos, 2000; Jordan and Wilson, 2004) . Previous studies showed that microtubule dynamics was crucial for cell function (Wilson and Jordan, 1995) . In addition, microtubule is extremely important in the process of mitosis in orchestrating the separation and segregation of chromosomes, which sheds lights that microtubule is an important target for the research and development of anticancer drugs (Risinger et al., 2009a; Stumpff et al., 2014) . All microtubule-targeted drugs can disrupt the dynamics of microtubule and induce mitosis arrest of tumor cells (McIntosh and Hering, 1991) . Anti-mitotic drugs can be classified into two groups, one inhibits microtubule polymerization, such as colchicine and vinorelbine, while the other stimulates microtubule depolymerization, such as paclitaxel and docetaxel (Desbene and Giorgi-Renault, 2002) .
Prostate cancer (PCa) is a kind of common malignant tumor in male genitourinary system. Among men, PCa is the most frequently diagnosed new cases of cancer and the second leading cause of cancer death in the United States (Siegel et al., 2015) . With the J P E T # 2 2 5 9 1 2 5 present, surgical treatment, radiation treatment, hormone treatment and chemical therapy are four most common therapeutic methods for PCa patients. Hormone treatment, which is also termed as androgen-deprivation therapy, is the critical therapeutic option for advanced PCa patients among the above four therapies (Jani and Hellman, 2003; Ponholzer et al., 2011) . Unfortunately, hormonal therapy just has a palliative benefit in the early stage of PCa treatment and the majority of patients eventually progress to androgen-independent or hormone-refractory PCa, which means androgen-deprivation therapy is no longer effective and the cancer continues to develop (Miyamoto et al., 2004) . Therefore, chemotherapy of the advanced hormone-refractory PCa draws much more attention over the last few decades. Some microtubule-targeted agents have been demonstrated overall survival benefit clinically (Suzman and Antonarakis, 2014). Nowadays, some chemo-drugs targeting at microtubule and tubulin including docetaxel, cabazitaxel, epothilones and vinorelbine have been clinically used as chemotherapy drugs for androgen-independent PCa (Caty et al., 1997; Kearns et al., 2013; Morganti et al., 2013) . Nevertheless, drug resistance often appears after prolonged treatment. Therefore, researching and developing some novel anti-microtubule candidates is a potential strategy for hormone-refractory PCa (Aneja et al., 2010) .
In this study, a novel compound with tetrahydro-β-carboline scaffold, named LG308
( Fig. 1A，MW : 308.3495), was synthesized, screened and identified as an anticancer agent in our laboratory. Our results indicated that LG308 induced G2/M cell cycle arrest through inhibiting microtubule polymerization and disrupting the microtubule This article has not been copyedited and formatted. The final version may differ from this version.
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Materials and methods

Synthesis of LG308
To a solution of 2-fluorophenylhydrazine hydrochloride (0.81 g, 5.00 mM) in 30 mL 3, 4, . The synthesis route of
LG308 is described in Supplemental Figure 1A . Sciences, East China Normal University. The antibodies used in this study were anti-cdc 2, p-cdc 2, cdc 25c, cyclin B1, Caspase 3, PARP, β -actin (Cell Signaling Technology), α -tubulin (Epitomics), CD31 (Abcam) and anti-phospho-Ser/Thr-Pro MPM-2 (Millipore). The compound LG308 was synthesized by our lab with the purity more than 98%.
Cell proliferation assay (Sulforhodamine B assay)
Cell proliferation inhibition assay was determined by Sulforhodamine B assay.
Briefly, 4000 cells per well were seeded in 96-well plates. After 24 h, cells were exposed to five different dose (0, 1, 5, 10, 20 μM) of LG308 for 72 h. Cells were fixed
Immunofluorescence staining
Immunofluorescence staining was performed according to previous report (Zhang et al., 2011) . Briefly, cells were seeded on gelatin-coated-glass cover slips. 24 h later, cells
were treated with different dose of LG308 for 24 h. Then cells were incubated with 4% paraformaldehyde for 20 min, washed with PBS, and treated with 0.5% Triton-X 100, washed with PBS. After blocking in 0.5% BSA, cells were incubated with primary antibody overnight at 4 o C before further incubation with secondary antibody at 37 for 1 h in the dark. Then DAPI was added for 5 min in the dark. Images were recorded by confocal microscopy (Leica).
Mitotic index assay
Mitotic index assay was performed according to previous report (Chang et al., 2011) with modification. Cells were seeded on gelatin-coated cover slips. After 24 h, four different doses (0, 5, 10, 20 μM) compound were added for 24 h. After fixed with 4% paraformaldehyde for 20 min at room temperature, cells were permeabilized with 0.2%
Triton-X 100 in PBS for 5 min. The nuclei were stained with DAPI. After washed with PBS, cells were visualized and photographed with Leica microscopy. Five random fields were counted and analyzed. Mitotic index was calculated by dividing the total number of examined cells by the number of cells in mitosis.
Western blotting
Cells were exposed to five different dose (0, 1, 5, 10, 20 
Viability assay
Viability assay was performed using the live/dead viability/cytotoxicity kit were counted for statistical analysis.
In vivo microtubule polymerization assay
In vivo microtubule polymerization assay was performed according to previous
reports ( 
PC-3M orthotopic tumor growth and metastasis
Male nude mice were anesthetized and placed under a sterile cover in a supine
position. An incision was made 3 mm above the pubic symphysis and the bladder and seminal vesicles were carefully lifted to expose the dorsal prostate. The PC-3M-luc cells suspension (1×10 6 cells in 0.05 mL PBS）was injected into the dorsal prostate Pettaway et al., 1996; Tuomela et al., 2008) . After inoculation, abdominal muscle layer and the skin were closed and sewed up, respectively. One week later, the consecutively for 20 days, with the measurement of body weight and IVIS image.
Hematoxylin and eosin (HE) and immunohistochemistry (IHC)
HE staining and immunohistochemistry were performed as reported previously (Zhang et al., 2012) .
T umors, liver and kidney were removed from sacrificed mice, fixed with 10% formaldehyde and then embedded in paraffin. Paraffinembedded tissues were sectioned at 5μm Sections. Tumor tissues were stained with MPM-2 (Millipore) and CD31 (Abcam). The HE staining of liver and kidney was performed according to standard protocol. Images were taken with Leica microscope. The results were analyzed using Image-Pro Plus 6.0 software.
Determination of LG308 in nude mouse plasma
Blood was sampled from mouse eyes at 10min, 30min, 1h, 2h, 4h, and 8h after intraperitoneal administration. The concentration of LG308 in plasma was determined by an Agilent 1290 LC system coupled with 6460 triple-quadrupole mass spectrometer (Agilent Technologies, USA). Chromatography separation was performed on a Phenomenex Kinetex XB-C18 column (3.0 × 100 mm, 2.6 μm). The mobile phase consisted of water (A) and acetonitrile (B) using gradient elution at a flow rate of 0.3 mL/min, and the injection volume was 4 μL. The detection of the ions was performed in the MRM mode, monitoring the transition of m/z 307.2 precursor to the m/z 159.9 product ion for LG308, and m/z 401.3 precursor to m/z 254 product ion for IS (an analogue of compound). The fragmentor and collision energy were optimized for
LG308 and IS, respectively. A liquid-liquid extraction method by ethyl acetate was used to isolate LG308 from plasma.
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Results
LG308 inhibits proliferation and colony formation of PCa cells LG308 induces cell cycle arrest of LNCaP and PC-3M cell lines
To verify the causal relation of the inhibitory cell proliferation and cell cycle arrest of LNCaP and PC-3M cells after treated with LG308, the cell cycle distribution was analyzed by flow cytometry.
LG308 was found to increase cell number at G2/M phase after 24 h treatment with raising concentration, accompanied by decreased cell number at S phase and G1 phase in LNCaP and PC-3M cell lines (Fig. 1D ) and similar cell cycle arrest effect was also detected in PNT1A cells (Supplemental Figure 1C) . Furthermore, proteins responsible for G2/M transition were measured by western blotting. As expected, the rational results were consistent with the cell cycle assay.
LG308 caused dose-dependent decreases in phosphorylated cdc2 and total cdc25c and an accumulation of cyclin B1 in PC -3M and LNCaP after 24h treatment (Fig. 1E) .
Meanwhile, the level of total cdc2 was not affected by the treatment of LG308 (Fig. 1E) .
Conclusively, these results indicated that LG308-induced cell cycles were arrested in G2/M phase before cell death occurred.
LG308 arrests cell cycle in mitotic phase
Next, the mitosis index assay was performed referred to the published report by staining the cells with DAPI to confirm whether cells were arrested at G2 or M phase (Chang et al., 2011) . As shown in Figure 2A , with an increasing dose of LG308, more cells were accumulated at M phase as indicated by condensed nuclei in PC-3M, and
LNCaP showed the similar M phase cells accumulation responding to LG308 treatment (Supplemental Figure 2A) . Furthermore, we conducted the western blotting assay to detect the MPM-2, a marker for mitotic cells. As Figure 2B shown, MPM-2 was up-regulated accompanied by the increase of LG308 concentration. The up-regulation of MPM-2 were also observed in LNCaP cells (Supplemental Figure 2B ).
LG308 disrupts microtubule organization of PC-3M and LNCaP cells
Microtubules are composed of α-tubulin and β-tubulin heterodimers and plays critical roles in regulating cell cycle and cell proliferation (Jordan and Wilson, 2004 ).
Conventionally, α-tubulin and β-tubulin heterodimers exist in two forms, soluble monomer and polymerized tubulin heterodimers. Our results showed that inhibitory effects of LG308 on PCa cell growth was related to cell mitosis arrest, which might be regulated by microtubular dynamics. The in vivo microtubule polymerization assay was performed on PC-3M and LNCaP cells to investigate the effect of LG308 on microtubule polymerization. After soluble and polymerized tubulin extracted, we discovered that polymerized tubulin decreased in a dose-dependent manner in response to LG308 treatment with a peak shown at dose 10mM (Fig. 2C) . It was then examined how LG308 affected microtubule by immunofluoresce staining of the microtubule. We found most of cells were affected (data not shown). Furthermore, as shown in Figure   2D , cells exposed to LG308 presented disorganized microtubule distribution and more diffuse staining occurred throughout the cytoplasm with LG308 increased, which was similar to those of colchicine-induced microtubule change. In contrast, 50 nM of paclitaxel dramatically promoted microtubule polymerization with an increase in the density of cellular microtubules and formation of long thick microtubule bundles.
Furthermore, as showed in Figure 2E , cells without treatment of LG308 presented intact spindle assembly, while spindle structure was disrupted and showed an irregular organization with scattered stain increased after treatment of LG308. This phenomenon was also similar to that of spindle structure changed after the induction of colchicine treatment, with a reverse phenomenon caused by paclitaxel. The same results were also observed in LNCaP cells (Supplemental Figure 3A and 3B).
LG308 provokes PCa cell apoptosis as well as cell death
Besides the anti-microtubule activity, the effects of LG308 were further explored on apoptosis and cell death of PCa cells. To further identify whether LG308 could induce apoptosis in PCa cells, apoptosis analysis was investigated by staining PC-3M cells with Annexin V-FITC/PI. Results showed that LG308 induced apoptosis of PC-3M in both concentration-dependent and time-dependent manners. As shown in Fig. 3A and 3B, apoptotic cells raised from 1.79% to 11.39% with LG308 dose increased from 0 μM to 20 μM after 48 h treatment and raised from 2.23% to 17.94% along with treatment time increased from 0 h to 72 h at 10 μM. Then some downstream apoptotic proteins, such as caspse-3 and PARP were detected. Caspse-3 was down-regulated in a dose-dependent manner at 48 h and PARP was down-regulated by the increase of
LG308 concentration at 72 h in PC-3M cells (Supplemental Figure 2C) . Meanwhile, a cell viability assay was also carried out on PC-3M and LNCaP cells using the live/dead viability/cytotoxicity kit (Molecular Probes) to investigate whether LG308 resulted in the death of PCa cells. As revealed in Figure 3C , the percentage of dead cells ascended with the increase of LG308 concentration. These data indicated that LG308 also provoked apoptosis and cell death in addition to its effect on cell cycle. LG308 inhibits the growth of PC-3M tumor xenograft
Above data suggested that LG308 inhibit PCa cell in vitro. Naturally, the effects of
LG308 (25mg/kg/d) on PC-3M tumor xenograft was tested to investigate the effect of
LG308 on PCa in vivo. As shown in Figure 4A, LG308 inhibited the growth of PC-3M tumor compared to the control group. LG308 at the given concentration had little effect on the body weights of the
LG308-treated mice (Fig. 4A) , and the HE staining results of liver and kidney confirmed the same conclusion that LG308 presented no obvious influence to the anatomical morphologies of mice administrated with LG308 ( Fig. 4C) , when compared to the control group. These data may suggested that LG308 had low toxicity to mouse at the curative dose. At the same time, less cell proliferation as indicated by probes anti-Ki-67 and accumulation of M phase cells as indicated by probes anti-MPM2 (Fig.   4B ) were detected in LG308 treated tumors, while no significant change of angiogenesis indicated by probes anti-CD31 (Supplemental Figure 4A) . Thus, LG308
exerted potent antitumor efficacy toward PC-3M tumor xenograft in vivo.
LG308 suppresses PC-3M orthotopic tumor growth and metastasis in vivo before cells were injected into the dorsal prostate. As Figure 5A shown, at the day the nude mice were sacrificed, the average normalized photon flux of the 10 mg/kg/day of
LG308 treated group and 25 mg/kg/day of LG308 treated group was 35.27 ± 18.45 percent and 11.04 ± 9.95 percent of that of control group, respectively. The average tumor volume of control group was 1230.71 ± 663.10 mm 3 , while that of 10 and 25 mg/kg/day of LG308 treated group were 388.18 ± 46.98 mm 3 and 209.95 ± 144.47 mm 3 , respectively (Fig. 5D ). The tumor of control group spread to other organs obviously, like intestine, liver, kidney and spleen. However, LG308 treated group didn't develop obvious metastasis (Fig. 5B ). And at the same time, treatment of LG308 with the given concentration had little influence on the body weights of the LG308-treated mice, compared with control group (Fig. 5C ). In conclusion, these results indicate that
LG308 not only inhibits the growth of PC-3M tumor xenograft, but also hinders PC-3M orthotopic tumor growth and metastasis in vivo.
The concentration of LG308 in nude mouse plasma
As shown in Supplemental Figure 4B , the concentration of LG308 in nude mouse plasma at 10 min was 6885.01 ng/mL and 3580.55 ng/mL after intraperitoneal administration of LG308 with the doses at 25 mg/kg and 10 mg/kg, which far exceed its effective concentration in vitro. And it could still reach 362.19 ng/mL and 38.25 ng/mL after 8h, respectively. These data could support its pharmacological effects in vivo.
Discussion
In the present study, we described a small molecular compound LG308 that inhibits prostatic tumor growth and metastasis.
LG308 inhibited the proliferation of androgen dependent (LNCaP, 22RV1) or independent (PC-3M, DU145, PC3) PCa cells in vitro and suppressed PC-3M tumor growth and metastasis via blocking the polymerization of microtubule.
In the past few years, great strides have been made for identifying effective and new therapies for PCa (Shore et al., 2012) . But most PCa cases ultimately relapsed and progressed to intractable castration-resistant PCa (CRPC)(Xu and Zhang, 2014). and LNCaP cells. Moreover the scattered staining increased with the concentration increase of LG308.In accordance with the fact that microtubule-targeting agents arrest the cell cycle at G2/M phase, our results showed that LG308 induced a G2/M blockade, as indicated by flow cytometry analysis (Fig. 1D) . We further investigated the in-depth molecular mechanism of cell cycle arrest induced by LG308. Cyclin B and cdc2 kinase regulated the start of M phase (King and Cidlowski, 1995) . Previous research have shown that the activation of cdc2 kinase is dependent on accumulation of cyclin B and dephosphorylation of cdc2 (Chiang et al., 2013) . We observed an obvious dose-dependent decrease of phosphorylated cdc2 protein and total cdc25c
protein in PC-3M and LNCaP, and an accumulation of cyclin B1 protein in PC-3M.
Meanwhile, the level of total cdc2 was not affected by the treatment of LG308.
Previous studies have shown that MPM2 was a protein related to mitotic (Scatena et al., 1998) . And the MPM-2 up-regulation accompanied by the increase of LG308 concentration was detected in our study. Cell cycle arrest at mitotic phase might be an upstream event leading to apoptotic (Jordan and Wilson, 2004) . Significant cell apoptosis and cell death induced by LG308 were detected by flow cytometry analysis and cell live/dead assay in PCa cells (Fig. 3A, 3B and 3C ). In conclusion, LG308 is a promising anticancer candidate with anti-microtubule activity for the treatment of prostate cancer according to our research.
Besides the primary advantage of LG308 that it possesses remarkable anticancer effectiveness in vitro and in vivo, another advantage of LG308 is its acceptable toxicity. anti-cancer drugs for several years (Zhang et al., 2015) but many obstacles to effective treatment with currently approved agents are present, incorporating significant side effects (Risinger et al., 2009b; Novio et al., 2014) . According to our research, LG308
has acceptable toxicity. Although LG308 induced cell cycle arrest in PNT1A, a human normal prostate epithelium immortalized cell line, as well as PCa cell lines, and it only shows slight proliferation inhibition in PNT1A cells with the effective concentration in PCa cell lines.
LG308 at the effective concentration had little effect on the body weight of the LG308-treated mice in vivo, when compared to the control group in subcutaneous xenograft tumor model and orthotopic growth and metastasis model ( Fig. 4A and Fig. 5C ). There was also no significant difference in HE staining results of liver and kidney between LG308-treated group and control group (Fig. 4C) .
Our study had a few limitations. Although LG308 had the inhibitory effect on microtubule polymerization, we still did not know the specific. It was not clear whether
LG308 exerted its inhibitive effect on microtubule polymerization by direct combination with tubulin or through some other ways. Meanwhile, apoptosis and cell death induced by anti-mitotic agents were known to be related to alternations of cellular signaling pathways, but the specific mechanism of LG308 in PCa were not clear enough. What's more, we also tested some symbolic parameters of pharmacokinetics and pharmacodynamics (PDPK) about LG308 in vivo, more study need to determine more specific PDPK characteristics for its preclinical study in the future.
In conclusion, our data demonstrated LG308, a novel small molecule compound designed and synthesized, was efficacious in suppressing the growth and metastasis of PCa both in vitro and in vivo via perturbing the microtubule polymerization primarily.
As a result, LG308 can be considered as a new potential drug candidate in for PCa, and it was worth further research and investigation. For Ki-67 and MPM-2 immunohistochemical staining, sections which cut from the paraffin blocks of PC-3M xenograft were carried out using Ki-67 or MPM-2 antibody and the positive cells (brown color) of each group were counted. n=3; ***, P<0.001.
Figure Legends
C, Liver and kidney hematoxylin and eosin (HE) staining of control and
LG308-treatment group. n=8; **, P<0.01.
SUPPLEMENTAL DATA
LG308 LG308-treatment group and control group. B, The concentration of LG308 in nude mouse plasma after intraperitoneal administration of LG308 with the doses at 25 mg/kg and 10 mg/kg.
